Targets › UGCG
4 programs from 4 companies in 11 trials: 10 Phase 3, 1 Phase 2; Metabolic and endocrine; next expected readout Jan 2027.
Participates in the initial step of the glucosylceramide-based glycosphingolipid/GSL synthetic pathway at the cytosolic surface of the Golgi. Catalyzes the transfer of glucose from UDP-glucose to ceramide to produce glucosylceramide/GlcCer (such as beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine). (UniProt, Q16739)
Open in Phaseline: the race on UGCG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sanofi | Venglustat (GZ402671) Ceramide glucosyltransferase inhibitor | UGCG | Phase 3 | Gaucher's Disease Type III; Fabry Disease | Jan 2027 |
| Amicus Therapeutics | Miglustat (AT2221) Ceramide glucosyltransferase inhibitor | UGCG | Phase 3 | Pompe Disease (Late-onset); Glycogen Storage Disease Type II Infantile Onset | Mar 2027 |
| Azafaros | Nizubaglustat (AZ-3102) Glucosidase inhibitor | GBA, UGCG | Phase 3 | Gangliosidoses, GM2; Niemann-Pick Type C Disease; GM2 Gangliosidosis | Jun 2027 |
| Idorsia Pharmaceuticals | Lucerastat Ceramide glucosyltransferase inhibitor | UGCG | Phase 3 | Fabry Disease | Feb 2029 |
Fabry Disease (4) Niemann-Pick Type C Disease (2) Pompe Disease (Late-onset) (1) Glycogen Storage Disease Type II Infantile Onset (1) Gaucher's Disease Type III (1) Gangliosidoses, GM2 (1) GM2 Gangliosidosis (1)
small molecule (3), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.